A Computer-Based Intervention for Distance Caregivers of Parents With Advanced Cancer

NCT ID: NCT02128373

Last Updated: 2015-02-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

7 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-11-30

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This pilot clinical trial studies the feasibility and effectiveness of a new computer-based communication intervention in supporting distance caregivers of patients with advanced lung or brain cancer. Unlike local caregivers, distance caregivers often receive little, if any, professional support and have limited communication with the oncology team. Using a computer-based communication intervention to allow distance caregivers the opportunity to participate in a physician visit, have questions and concerns addressed, and meet members of the oncology team may help reduce stress.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. What is the relationship of primary stressors (type and stage/grade of cancer, and patient quality of life \[QOL\]) and structural factors/stressors (age, gender, race, and education) with patient and caregiver psychological outcomes at baseline? II. What are the effects of the Communication with Long Distance Caregivers Offering a Supportive Electronic Resource (CLOSER) intervention on distance caregiver psychological outcomes (anxiety and distress), controlling for primary stressors (type and stage/grade of cancer, and patient quality of life), distance caregiver structural factors/stressors (caregiver age, gender, race, and employment), and baseline anxiety and distress? III. What are the effects of the CLOSER intervention on patient psychological outcomes (anxiety and distress), controlling for primary stressors (type and stage/grade of cancer, and patient quality of life), distance caregiver structural factors/stressors (caregiver age, gender, race, and employment), and baseline anxiety and distress? IV. What is the feasibility (time, cost, resources and acceptability to patients, caregivers and clinicians) of using Adobe Connect, a computer-based web communication system, with the distance caregiver, the parent with advanced cancer, and the health care providers together in a routine follow-up oncology office visit? V. What is the experience of being a distance caregiver participating in the CLOSER intervention?

OUTLINE: Participants are assigned to 1 of 2 arms.

ARM I: Participants receive usual care for 5 weeks. During the week 5 office visit, distance caregivers are not present.

ARM II: Participants receive usual care for 5 weeks. During the week 5 visit, distance caregivers virtually attend using the CLOSER intervention with computer video and audio connection.

After completion of study, participants are followed up within 48-96 hours.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stage IV Lung Cancer Malignant Brain Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm I (usual care)

Participants receive usual care (care from physician, physician nurse, and social worker) for 5 weeks. During the week 5 office visit, distance caregivers are not present. In the pre-physician interview patients will verbally complete the FACT, POMS-B, Tension-Anxiety subscale, Distress Thermometer. Distance caregivers will verbally complete the POMS-B, Tension-Anxiety subscale, and Distress Thermometer

Group Type ACTIVE_COMPARATOR

Usual care

Intervention Type PROCEDURE

Health care provided by physician, physician's nurse, and social worker

Distress Thermometer

Intervention Type OTHER

Average score of a one item scale (range 0-10) where higher scores indicate more distress

Profile of Mood States (POMS-B)

Intervention Type OTHER

average score of five items scored 0-4 which describe how someone is feeling. Higher scores indicate increased discomfort

Quality of Life: Functional Assessment in Cancer Therapy - (FACT)

Intervention Type OTHER

Average score of FACT which quantitatively assesses brain cancer patient's physiological functional and quality of life. FACT questions are scored 0-4 with higher numbers indicating more functionality

Tension-Anxiety Subscale

Intervention Type OTHER

six item scale which asks to qualitatively describe which areas in you life are causing stress

Arm II (usual care with CLOSER intervention)

Participants receive usual care (care from physician, physician nurse, and social worker) for 5 weeks. During the week 5 office visit, distance caregivers will use a computer-assisted intervention to be present electronically with video and audio feed to provide psychosocial support. In the pre-physician interview patients will verbally complete the FACT, POMS-B, Tension-Anxiety subscale, Distress Thermometer. Distance caregivers will verbally complete the POMS-B, Tension-Anxiety subscale, and Distress Thermometer. Up to 96 hours after the week 5 visit, patients and caregivers will be interviewed about their experience during the intervention

Group Type EXPERIMENTAL

Usual care

Intervention Type PROCEDURE

Health care provided by physician, physician's nurse, and social worker

computer-assisted intervention

Intervention Type OTHER

Caregiver will virtually attend visit using the CLOSER intervention

Distress Thermometer

Intervention Type OTHER

Average score of a one item scale (range 0-10) where higher scores indicate more distress

Profile of Mood States (POMS-B)

Intervention Type OTHER

average score of five items scored 0-4 which describe how someone is feeling. Higher scores indicate increased discomfort

Quality of Life: Functional Assessment in Cancer Therapy - (FACT)

Intervention Type OTHER

Average score of FACT which quantitatively assesses brain cancer patient's physiological functional and quality of life. FACT questions are scored 0-4 with higher numbers indicating more functionality

Tension-Anxiety Subscale

Intervention Type OTHER

six item scale which asks to qualitatively describe which areas in you life are causing stress

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Usual care

Health care provided by physician, physician's nurse, and social worker

Intervention Type PROCEDURE

computer-assisted intervention

Caregiver will virtually attend visit using the CLOSER intervention

Intervention Type OTHER

Distress Thermometer

Average score of a one item scale (range 0-10) where higher scores indicate more distress

Intervention Type OTHER

Profile of Mood States (POMS-B)

average score of five items scored 0-4 which describe how someone is feeling. Higher scores indicate increased discomfort

Intervention Type OTHER

Quality of Life: Functional Assessment in Cancer Therapy - (FACT)

Average score of FACT which quantitatively assesses brain cancer patient's physiological functional and quality of life. FACT questions are scored 0-4 with higher numbers indicating more functionality

Intervention Type OTHER

Tension-Anxiety Subscale

six item scale which asks to qualitatively describe which areas in you life are causing stress

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Having a diagnosis of advanced lung cancer or malignant brain tumor for two to six months
* Receiving on-going care from the medical oncologist at the Seidman Cancer Center
* Having a primary and distance caregiver involved in their care, support, and/or care planning
* English as a primary language
* Capacity to provide informed consent, as validated by the oncologist


* Family caregiver of a patient with advanced lung cancer or malignant brain tumor
* Patient and distance caregiver perception that this caregiver's geographic location is such that precludes routine participation in medical appointments
* English as primary language
* Capable of providing informed consent
* Computer ownership with internet access

Exclusion Criteria

* No primary caregiver
* Enrolled in hospice


* Those who routinely participate in most of the patient's medical appointments (once or more per month)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Cancer Institute (NCI)

NIH

Sponsor Role collaborator

Case Comprehensive Cancer Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sara Douglas, RN, PhD

Role: PRINCIPAL_INVESTIGATOR

Case Comprehensive Cancer Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Case Comprehensive Cancer Center

Cleveland, Ohio, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NCI-2014-00812

Identifier Type: REGISTRY

Identifier Source: secondary_id

CASE3Z11

Identifier Type: -

Identifier Source: secondary_id

CASE 3Z11

Identifier Type: OTHER

Identifier Source: secondary_id

P30CA043703

Identifier Type: NIH

Identifier Source: secondary_id

View Link

CASE3Z11

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.